Search Results - "Golovics, Petra Anna"

High‐sensitivity C‐reactive protein for identification of disease phenotype, active disease, and clinical relapses in Crohn's disease: A marker for patient classification? by Sandor Kiss, Lajos, Papp, Maria, Dorottya Lovasz, Barbara, Vegh, Zsuzsanna, Anna Golovics, Petra, Janka, Eszter, Varga, Eva, Szathmari, Miklos, Lakatos, Peter Laszlo

“…Background: C‐reactive protein (CRP) is a traditional nonspecific marker of inflammation, with Crohn's disease (CD) being associated with a strong CRP…”
Get full text

Is There a Best First Line Biological/Small Molecule in IBD: Are We Ready for Sequencing? by Hahn, Gustavo Drügg, Golovics, Petra Anna, Wetwittayakhlang, Panu, Al Khoury, Alex, Bessissow, Talat, Lakatos, Peter Laszlo

“…Inflammatory bowel disease (IBD) is a chronic, life-long inflammatory condition of the gastrointestinal tract. Treatment strategy depends on the severity of…”
Get full text

Therapeutic drug monitoring in inflammatory bowel disease: The dawn of reactive monitoring by Albader, Farah, Golovics, Petra Anna, Gonczi, Lorant, Bessissow, Talat, Afif, Waqqas, Lakatos, Peter Laszlo

“…Inflammatory bowel disease (IBD) is a chronic condition that significantly affects the quality of life of its patients. Biologic drugs have been the mainstay…”
Get full text

Outcomes of Patients With Inflammatory Bowel Diseases Switched From Maintenance Therapy With a Biosimilar to Remicade by Ilias, Akos, Szanto, Kata, Gonczi, Lorant, Kurti, Zsuzsanna, Golovics, Petra Anna, Farkas, Klaudia, Schafer, Eszter, Szepes, Zoltan, Szalay, Balazs, Vincze, Aron, Szamosi, Tamas, Molnar, Tamas, Lakatos, Peter Laszlo

“…There is evidence that it is safe and effective for patients with inflammatory bowel diseases (IBD) to switch from maintenance therapy with an original…”
Get full text

Has there been a change in the natural history of Crohn's disease? Surgical rates and medical management in a population-based inception cohort from Western Hungary between 1977-2009 by Lakatos, Peter Laszlo, Golovics, Petra Anna, David, Gyula, Pandur, Tunde, Erdelyi, Zsuzsanna, Horvath, Agnes, Mester, Gabor, Balogh, Mihaly, Szipocs, Istvan, Molnar, Csaba, Komaromi, Erzsebet, Veres, Gabor, Lovasz, Barbara Dorottya, Szathmari, Miklos, Kiss, Lajos S, Lakatos, Laszlo

“…Medical therapy for Crohn's disease (CD) has changed significantly over the past 20 years with increasing use of immunosuppressives. In contrast, surgery rates…”
Get full text

Patient-Reported Outcome and Clinical Scores Are Equally Accurate in Predicting Mucosal Healing in Ulcerative Colitis: A Prospective Study by Golovics, Petra Anna, Gonczi, Lorant, Reinglas, Jason, Verdon, Christine, Pundir, Sheetal, Afif, Waqqas, Wild, Gary, Bitton, Alain, Bessissow, Talat, Lakatos, Peter L.

“…Background Optimal management of patients with ulcerative colitis (UC) requires the accurate, objective assessment of disease activity. Aims We aimed to…”
Get full text

Effectiveness, safety, and drug sustainability of biologics in elderly patients with inflammatory bowel disease: A retrospective study by Hahn, Gustavo Drügg, LeBlanc, Jean-Frédéric, Golovics, Petra Anna, Wetwittayakhlang, Panu, Qatomah, Abdulrahman, Wang, Anna, Boodaghians, Levon, Liu Chen Kiow, Jeremy, Al Ali, Maryam, Wild, Gary, Afif, Waqqas, Bitton, Alain, Lakatos, Peter Laszlo, Bessissow, Talat

“…BACKGROUNDBiologic therapy resulted in a significant positive impact on the management of inflammatory bowel disease (IBD) however data on the efficacy and…”
Get full text

Efficacy and Safety of the Biosimilar Infliximab CT-P13 Treatment in Inflammatory Bowel Diseases: A Prospective, Multicentre, Nationwide Cohort by Gecse, Krisztina B., Lovász, Barbara D., Farkas, Klaudia, Banai, János, Bene, László, Gasztonyi, Beáta, Golovics, Petra Anna, Kristóf, Tünde, Lakatos, László, Csontos, Ágnes Anna, Juhász, Márk, Nagy, Ferenc, Palatka, Károly, Papp, Mária, Patai, Árpád, Lakner, Lilla, Salamon, Ágnes, Szamosi, Tamás, Szepes, Zoltán, Tóth, Gábor T., Vincze, Áron, Szalay, Balázs, Molnár, Tamás, Lakatos, Péter L.

“…Background and Aims: Biosimilar infliximab CT-P13 is approved for all indications of the originator product in Europe. Prospective data on its efficacy,…”
Get full text

Association of extraintestinal manifestations and anaemia with disease outcomes in patients with inflammatory bowel disease by Vegh, Zsuzsanna, Kurti, Zsuzsanna, Gonczi, Lorant, Golovics, Petra Anna, Lovasz, Barbara Dorottya, Szita, Istvan, Balogh, Mihaly, Pandur, Tunde, Vavricka, Stephan R, Rogler, Gerhard, Lakatos, Laszlo, Lakatos, Peter Laszlo

“…Objective: The association between extraintestinal manifestations (EIMs) and disease activity suggest a common pathogenetic link with inflammatory bowel…”
Get full text

Mo1892 – Non-Medical Reverse Switch Between the Originator Infliximab and Its Biosimilar in Patients with Inflammatory Bowel Disease: Clinical Outcomes and Therapeutic Drug Monitoring by Gonczi, Lorant, Ilias, Akos, Szanto, Kata, Kurti, Zsuzsanna, Golovics, Petra Anna, Farkas, Klaudia, Schafer, Eszter, Szepes, Zoltán, Szalay, Balazs, Vincze, Aron, Szamosi, Tamas, Molnar, Tamas, Lakatos, Peter L.

Get full text

'Treat to Target' - Lessons Learnt by Kurti, Zsuzsanna, Vegh, Zsuzsanna, Golovics, Petra Anna, Lakatos, Peter Laszlo

“…Therapeutic management in inflammatory bowel diseases (IBD) has significantly changed in the last decades with the advent of biological therapy resulting in…”
Get more information

Mo1843 - Non-Medical Mandatory Reversed and Back and Forth Switch Between Infliximab and its Biosimilar: Early Clinical Outcomes by Ilias, Akos, Szanto, Kata, Gonczi, Lorant, Kurti, Zsuzsanna, Golovics, Petra Anna, Szamosi, Tamas, Schafer, Eszter, Farkas, Klaudia, Szepes, Zoltán, Molnar, Tamas, Vincze, Aron, Lakatos, Peter L.

Get full text

Evolution of disease phenotype in adult and pediatric onset Crohn's disease in a population-based cohort by Lovasz, Barbara Dorottya, Lakatos, Laszlo, Horvath, Agnes, Szita, Istvan, Pandur, Tunde, Mandel, Michael, Vegh, Zsuzsanna, Golovics, Petra Anna, Mester, Gabor, Balogh, Mihaly, Molnar, Csaba, Komaromi, Erzsebet, Kiss, Lajos Sandor, Lakatos, Peter Laszlo

“…To investigate the evolution of disease phenotype in adult and pediatric onset Crohn's disease (CD) populations, diagnosed between 1977 and 2008. Data of 506…”
Get full text

Safety of Biological Therapies in Elderly Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis by Hahn, Gustavo Drügg, Golovics, Petra Anna, Wetwittayakhlang, Panu, Santa Maria, Dirlene Melo, Britto, Usiara, Wild, Gary Edward, Afif, Waqqas, Bitton, Alain, Bessissow, Talat, Lakatos, Peter Laszlo

“…Newer biologics appeared safer in landmark clinical trials, but their safety is understudied in vulnerable populations. The aim of the present study was to…”
Get full text

Quality of care indicators in inflammatory bowel disease in a tertiary referral center with open access and objective assessment policies by Gonczi, Lorant, Kurti, Zsuzsanna, Golovics, Petra Anna, Lovasz, Barbara Dorottya, Menyhart, Orsolya, Seres, Anna, Sumegi, Liza Dalma, Gal, Alexander, Ilias, Akos, Janos, Papp, Gecse, Krisztina Barbara, Bessisow, Talat, Afif, Waqqas, Bitton, Alain, Vegh, Zsuzsanna, Lakatos, Peter Laszlo

“…In the management of inflammatory bowel diseases, there is considerable variation in quality of care. The aim of this study was to evaluate structural,…”
Get full text

Is early limited surgery associated with a more benign disease course in Crohn's disease? by Golovics, Petra Anna, Lakatos, Laszlo, Nagy, Attila, Pandur, Tunde, Szita, Istvan, Balogh, Mihaly, Molnar, Csaba, Komaromi, Erzsebet, Lovasz, Barbara Dorottya, Mandel, Michael, Veres, Gabor, Kiss, Lajos S, Vegh, Zsuzsanna, Lakatos, Peter Laszlo

“…To analyze the difference in disease course and need for surgery in patients with Crohn's disease (CD). Data of 506 patients with incident CD were analyzed…”
Get full text

Prediction of Short- and Medium-term Efficacy of Biosimilar Infliximab Therapy. Do Trough Levels and Antidrug Antibody Levels or Clinical And Biochemical Markers Play the More Important Role? by Gonczi, Lorant, Vegh, Zsuzsanna, Golovics, Petra Anna, Rutka, Mariann, Gecse, Krisztina Barbara, Bor, Renata, Farkas, Klaudia, Szamosi, Tamás, Bene, László, Gasztonyi, Beáta, Kristóf, Tünde, Lakatos, László, Miheller, Pál, Palatka, Károly, Papp, Mária, Patai, Árpád, Salamon, Ágnes, Tóth, Gábor Tamás, Vincze, Áron, Biro, Edina, Lovasz, Barbara Dorottya, Kurti, Zsuzsanna, Szepes, Zoltan, Molnár, Tamás, Lakatos, Péter L.

“…Abstract Background and Aims: Biosimilar infliximab CT-P13 received European Medicines Agency [EMA] approval in June 2013 for all indications of the originator…”
Get full text

Low incidence of venous thromboembolism in inflammatory bowel diseases: prevalence and predictors from a population-based inception cohort by Vegh, Zsuzsanna, Golovics, Petra Anna, Lovasz, Barbara Dorottya, Kurti, Zsuzsanna, Gecse, Krisztina Barbara, Szita, Istvan, Balogh, Mihaly, Pandur, Tunde, Lakatos, Laszlo, Lakatos, Peter Laszlo

“…AbstractObjective. Patients with inflammatory bowel diseases (IBD) are considered to have an increased risk for venous thromboembolism (VTE). The aim of the…”
Get full text

Reply by Golovics, Petra Anna, Vegh, Zsuzsanna, Lakatos, Peter Laszlo

Get full text

Increased Prevalence of Myocardial Infarction and Stable Stroke Proportions in Patients with Inflammatory Bowel Diseases in Quebec in 1996-2015 by Golovics, Petra Anna, Verdon, Christine, Wetwittayakhlang, Panu, Filliter, Christopher, Gonczi, Lorant, Hahn, Gustavo Drügg, Wild, Gary E, Afif, Waqqas, Bitton, Alain, Bessissow, Talat, Brassard, Paul, Lakatos, Peter L

“…Chronic inflammatory diseases are linked to an increased risk of atherothrombotic events, but the risk associated with inflammatory bowel disease (IBD) is…”
Get full text